Medicine News and Research

RSS

WillWalk to raise funds for human stem cell trials for people with SCI

WillWalk, an Austin based non-profit organization has committed itself to be at the forefront of ending Paralysis. WillWalk will raise $3 million to help fund the first non-controversial human stem cell trials for people with Spinal Cord Injury (SCI).

14 Sep 2009

Phase 3 results of TARGET 1 and TARGET 2 clinical trials released

Salix Pharmaceuticals, Ltd. today announced the successful outcome of two Phase 3, randomized, double-blind, placebo-controlled, multicenter trials, TARGET 1 and TARGET 2, designed to evaluate the efficacy and safety of rifaximin 550 mg TID in the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS).

14 Sep 2009

National Conference on Latinos and AIDS

To educate healthcare professionals on how to improve the Latino community's access to HIV/AIDS treatment and care, Minority Health Care Communications (MHCC) will hold the National Conference on Latinos and AIDS, September 14-15th, 2009, at the New York Academy of Medicine in New York.

14 Sep 2009

Innovative stroke treatment device to minimize brain damage

Driven by the emergency-room maxim, "Time is brain," NeuroInterventions, Inc. is prototyping an innovative stroke treatment device designed to speed up the restoration of blood flow and thus minimize brain damage.

14 Sep 2009

Phase III clinical trial results of DAR-31 published

Gilead Sciences, Inc. today announced the publication of data from DAR-311 (DORADO), a Phase III clinical trial evaluating the company’s once-daily oral endothelin receptor antagonist (ERA) darusentan as an add-on treatment for resistant hypertension, defined as the failure to achieve blood pressure goal while adhering to full doses of an appropriate three (or more) drug antihypertensive regimen that includes a diuretic.

14 Sep 2009

Communities can make an impact on childhood obesity rates

Parents strive to help children stay fit and healthy. Now, a new report says local government should do its part, too.

14 Sep 2009

Influenza patients treated with Tamiflu has higher survival rates

Roche announced today that two new observational studies concluded that influenza patients treated with Tamiflu(R) (oseltamivir phosphate) had significantly higher survival rates than untreated patients.

14 Sep 2009

FDA approves Theravance's VIBATIV for treating complicated skin and skin structure infections

Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved VIBATIV™ (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.

14 Sep 2009

New findings could yield effective therapies for multiple sclerosis

A Mayo Clinic study has found that two genes in mice were associated with good central nervous system repair in multiple sclerosis (MS). These findings give researchers new hope for developing more effective therapies for patients with MS and for predicting MS patients' outcomes.

14 Sep 2009

Recent releases: HIV and nutrition; new global health journal; male circumcision; Chagas disease; malaria research methods

"Despite calls from national and international organizations to integrate HIV and nutritional programs, data are lacking on how such programs can be effectively implemented in resource-poor settings, on the optimum content and duration of nutritional support, and on ideal target recipients," write the authors of a Clinical Infectious Diseases review that examines the relationship between HIV, nutritional deficiencies and food insecurity.

14 Sep 2009

Newly discovered molecular circuit helps maintain proper body metabolism

Researchers at the University of Pennsylvania School of Medicine have discovered a molecular circuit involving heme that helps maintain proper metabolism in the body, providing new insights into metabolic disorders such as obesity and diabetes.

14 Sep 2009

Study estimates economic benefits of lowering sodium consumption

Reducing Americans' average intake of sodium to the amount recommended by health officials could save the nation as much as $18 billion annually in avoided health care costs and improve the quality of life for millions of people, according to a new RAND Corporation study.

14 Sep 2009

Bangkok Hospital Group and IBM to provide quality healthcare in Thailand

Bangkok Hospital Group is working with IBM (NYSE: IBM) to enhance its patient care services to provide smarter healthcare in Thailand. Delivering on its commitment to provide the highest quality, internationally-accepted standards of medical services, Bangkok Hospital Group continues to invest in best-in-class information technology.

14 Sep 2009

Knowledge gap regarding the use of breast cancer tests

A new study finds that there is little information available about the use of new testing technologies and targeted therapies in breast cancer, specifically the anti-cancer drug trastuzumab (Herceptin).

14 Sep 2009

Lack of awareness affects surgery referrals

Overblown fears about surgical risk and lack of awareness about the risk of not operating are among the reasons only half of eligible patients were referred for mitral valve repair, according to a study by doctors at the University of Michigan Cardiovascular Center.

14 Sep 2009

High-fat foods can induce binge eating

Findings from a new UT Southwestern Medical Center study suggest that fat from certain foods we eat makes its way to the brain. Once there, the fat molecules cause the brain to send messages to the body's cells, warning them to ignore the appetite-suppressing signals from leptin and insulin, hormones involved in weight regulation.

14 Sep 2009

Phase 2 MS clinical trial data continues to show durable reductions in relapse rate

Genzyme Corporation reported today that four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial continued to show durable reductions in relapse rate and sustained accumulation of disability three years after the majority of patients received their last course of the investigational compound alemtuzumab.

14 Sep 2009